Nonproportional Hazards—An Evaluation of the MaxCombo Test in Cancer Clinical Trials

Yuan-Li Shen, Xin Wang, Mushti Sirisha, Flora Mulkey, Jiaxi Zhou, Xin Gao, Lijun Zhang, Thomas Gwise, Shenghui Tang, Marc R. Theoret

Type: Article

Publication Date: 2021-12-02

Citations: 7

DOI: https://doi.org/10.1080/19466315.2021.2008485

View

Locations

Statistics in Biopharmaceutical Research - View

Similar Works

Action	Title	Year	Authors
+ PDF Chat	Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis	2019	Ray Lin Ji Lin Satrajit Roychoudhury Keaven M. Anderson Tianle Hu Bo Huang Larry Leon Jason J. Z. Liao Rong Liu Xiaodong Luo
+	Rejoinder to Comments on “Non-Proportional Hazards – An Evaluation of the MaxCombo Test in Cancer Clinical Trials”	2023	Yuan-Li Shen Sirisha L. Mushti Flora Mulkey Thomas Gwise Xin Wang Jiaxi Zhou Xin Gao Shenghui Tang Marc R. Theoret Richard Pazdur
+	Testing and Interpreting the “Right” Hypothesis—Comment on “Non-proportional Hazards — An Evaluation of the MaxCombo Test in Cancer Clinical Trials”	2022	Martin Posch Robin Ristl Franz König
+ PDF Chat	Statistical Considerations for Evaluating Treatment Effect under Various Non-proportional Hazard Scenarios	2024	Xinyu Zhang Erich J. Greene Ondřej Bláha Wei Wei
+ PDF Chat	Statistical considerations for evaluating treatment effect under various non-proportional hazard scenarios	2025	Xinyu Zhang Erich J. Greene Ondřej Bláha Wei Wei
+	Comment on “Non-Proportional Hazards – an Evaluation of the MaxCombo Test in Cancer Clinical Trials” by the Cross-Pharma Non-Proportional Hazards Working Group	2023	Ray Lin Pralay Mukhopadhyay Satrajit Roychoudhury Keaven M. Anderson Tianle Hu Bo Huang Larry Leon Jason J. Z. Liao Ji Lin Rong Liu
+ PDF Chat	Statistical considerations in long-term efficacy evaluation of anti-cancer therapies	2023	Ruobing Li Jingyi Zhang Jingzhao Wang Jun Wang
+ PDF Chat	Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?	2019	Boris Freidlin Edward L. Korn
+	<scp>Two‐sample</scp> inference procedures under nonproportional hazards	2023	Y.T. Tai Weijing Wang Martin T. Wells
+	Statistical methods of indirect comparison with real-world data for survival endpoint under non-proportional hazards	2022	Zihan Lin Dan Zhao Junjing Lin Ai Ni Jianchang Lin
+	A neutral comparison of statistical methods for time-to-event analyses under non-proportional hazards	2023	Florian Klinglmüller Tobias Fellinger Franz König Tim Friede Andrew C. Hooker Harald Heinzl Martina Mittlböck Jonas Brugger Maximilian Bardo Cynthia Huber
+	Testing Treatment Effect in Randomized Clinical Trials With Possible Nonproportional Hazards	2017	Andrea Callegaro Bart Spiessens
+ PDF Chat	Choice and Interpretation of Statistical Tests Used When Competing Risks Are Present	2008	James J. Dignam Maria N. Kocherginsky
+	Supplementary Data S2 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Data from Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications	2023	Rifaquat Rahman Geoffrey Fell Steffen Ventz Andrea Arfè Alyssa M. Vanderbeek Lorenzo Trippa Brian M. Alexander
+	Data from Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications	2023	Rifaquat Rahman Geoffrey Fell Steffen Ventz Andrea Arfè Alyssa M. Vanderbeek Lorenzo Trippa Brian M. Alexander
+ PDF Chat	Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications	2019	Rifaquat Rahman Geoffrey Fell Steffen Ventz Andrea Arfé Alyssa M. Vanderbeek Lorenzo Trippa Brian M. Alexander
+ PDF Chat	Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials	2022	Pralay Mukhopadhyay Jiabu Ye Keaven M. Anderson Satrajit Roychoudhury Eric H. Rubin Susan Halabi Richard J. Chappell
+	Supplementary Table S1 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+ PDF Chat	Quantifying treatment differences in confirmatory trials under non-proportional hazards	2020	José L. Jiménez

Cited by (8)

Action	Title	Year	Authors
+	Dealing With Nonproportional Hazards in Coronary Revascularisation Studies	2023	Lucas C. Godoy Dennis T. Ko Michael E. Farkouh Baiju R. Shah Peter C. Austin
+ PDF Chat	Comparison between asymptotic and re-randomisation tests under non-proportional hazards in a randomised controlled trial using the minimisation method	2024	Ryusei Kimura Shogo Nomura Kengo Nagashima Yasunori Sato
+ PDF Chat	Simultaneous inference procedures for the comparison of multiple characteristics of two survival functions	2024	Robin Ristl Heiko Götte Armin Schüler Martin Posch Franz König
+ PDF Chat	Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials	2022	Pralay Mukhopadhyay Jiabu Ye Keaven M. Anderson Satrajit Roychoudhury Eric H. Rubin Susan Halabi Richard J. Chappell
+	Comment on “Non-Proportional Hazards – an Evaluation of the MaxCombo Test in Cancer Clinical Trials” by the Cross-Pharma Non-Proportional Hazards Working Group	2023	Ray Lin Pralay Mukhopadhyay Satrajit Roychoudhury Keaven M. Anderson Tianle Hu Bo Huang Larry Leon Jason J. Z. Liao Ji Lin Rong Liu
+	Rejoinder to Comments on “Non-Proportional Hazards – An Evaluation of the MaxCombo Test in Cancer Clinical Trials”	2023	Yuan-Li Shen Sirisha L. Mushti Flora Mulkey Thomas Gwise Xin Wang Jiaxi Zhou Xin Gao Shenghui Tang Marc R. Theoret Richard Pazdur
+	Testing and Interpreting the “Right” Hypothesis—Comment on “Non-proportional Hazards — An Evaluation of the MaxCombo Test in Cancer Clinical Trials”	2022	Martin Posch Robin Ristl Franz König
+ PDF Chat	Statistical considerations for evaluating treatment effect under various non-proportional hazard scenarios	2025	Xinyu Zhang Erich J. Greene Ondřej Bláha Wei Wei

Citing (11)

Action	Title	Year	Authors
+	Proportional hazards tests and diagnostics based on weighted residuals	1994	Patricia M. Grambsch Terry M. Therneau
+	Partial residuals for the proportional hazards regression model	1982	David Schoenfeld
+	The estimation of average hazard ratios by weighted Cox regression	2009	M. Schemper Samo Wakounig Georg Heinze
+	A class of rank test procedures for censored survival data	1982	David P. Harrington Thomas R. Fleming
+	Consequences of Delayed Treatment Effects on Analysis of Time-to-Event Endpoints	2007	Gil D. Fine
+ PDF Chat	Estimating average regression effect under non-proportional hazards	2000	Ronghui Xu
+ PDF Chat	Versatile Tests for Comparing Survival Curves Based on Weighted Log-rank Statistics	2016	Theodore Karrison
+ PDF Chat	Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?	2019	Boris Freidlin Edward L. Korn
+	Rejoinder to Letter to the Editor “The Hazards of Period Specific and Weighted Hazard Ratios”	2020	Ray Lin Ji Lin Satrajit Roychoudhury Keaven M. Anderson Tianle Hu Bo Huang Larry Leon Jason J. Z. Liao Rong Liu Xiaodong Luo
+ PDF Chat	Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group	2021	Satrajit Roychoudhury Keaven M. Anderson Jiabu Ye Pralay Mukhopadhyay
+	The Strong Null Hypothesis and the MaxCombo Test: Comment on “Robust Design and Analysis of Clinical Trials with Nonproportional Hazards: A Straw Man Guidance form a Cross-Pharma Working Group.”	2021	Dominic Magirr Carl‐Fredrik Burman